Balfaxar Market Report 2026

Balfaxar Market Overview

• The Balfaxar market growth in the historic period has been driven by widespread use of vitamin k antagonists, need for urgent bleeding control • Market expansion is supported by increase in elderly patient surgeries, rising anticoagulant usage • Growth Driver: Increasing Prevalence Of Blood Disorders Fueling The Growth Of The Market Due To Rising Demand For Rapid And Effective Anticoagulation Reversal Solutions • Market Trend: Advancements In Prothrombin Complex Concentrate For Bleeding Disorder Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Balfaxar Market?

Balfaxar is a non-activated prothrombin complex concentrate (4F-PCC) designed to rapidly reverse the effects of vitamin K antagonists in adult patients undergoing surgery or invasive procedures. By replenishing deficient clotting factors, Balfaxar restores normal blood coagulation and helps minimize bleeding risks.  The main types of balfaxar formulation are 4-factor prothrombin complex concentrate and 3-factor prothrombin complex concentrate. The 4-factor prothrombin complex concentrate contains factors II, VII, IX, and X to restore clotting factor balance and manage bleeding in patients with bleeding disorders or during surgery. It shows various types of clinical indications, such as urgent reversal of VKA therapy and coagulation factor replacement, and is distributed by several distribution channels, including hospitals and ambulatory surgery centers, specialty clinics, and others. It is used by various end users, including adult patients and geriatric patients.

What Is The Balfaxar Market Growth Forecast?

The growth in the forecast period can be attributed to increase in elderly patient surgeries, rising anticoagulant usage, expansion of trauma centers, improved awareness of rapid reversal therapies, favorable clinical guidelines. Major trends in the forecast period include rising use of pccs for anticoagulant reversal, increased demand in emergency surgical settings, preference for rapid acting coagulation products, growth in aging surgical population, expansion of hospital based emergency care.

Global Balfaxar Market Segmentation

1) By Formulation: 4-Factor Prothrombin Complex Concentrate, 3-Factor Prothrombin Complex Concentrate 2) By Clinical Indication: Urgent Reversal Of VKA Therapy, Coagulation Factor Replacement 3) By Distribution Channel: Hospitals And Ambulatory Surgery Centers, Specialty Clinics, Other Distribution Channels 4) By End-User: Adult Patients, Geriatric Patients

What Are The Drivers Of The Balfaxar Market?

The increasing prevalence of blood disorders is expected to propel the growth of the balfaxar market going forward. Blood disorders refer to conditions that affect the components of blood, including red blood cells, white blood cells, platelets, or plasma. The increasing incidence of blood disorders is primarily due to the rising prevalence of chronic diseases, which directly impact blood health and require ongoing monitoring. Balfaxar aids in managing blood disorders by providing rapid and effective reversal of anticoagulation, making it crucial for patients experiencing major bleeding or requiring urgent surgery. It enhances clinical outcomes by delivering concentrated clotting factors that restore hemostasis quickly, improving treatment efficiency and patient safety. For instance, in July 2025, according to the National Blood Authority, an Australia-based blood management agency, there were 2,788 patients living with hereditary haemophilia A (HMA) in 2023-2024, up from 2,681 patients in 2022-2023. Therefore, the rising incidence of blood disorders is driving the growth of the balfaxar industry. The rising surgical procedures are expected to propel the growth of the balfaxar market going forward. Surgical procedures involve manual or instrumental techniques to diagnose, treat, or repair conditions in the body. Surgical procedures are driven by advancements in medical technology, increased healthcare access, and a growing demand for cosmetic and corrective treatments. Balfaxar quickly reverses the effects of vitamin K antagonists (VKAs), restoring normal blood clotting and preventing excessive bleeding during surgery. This ensures proper hemostasis, reducing the risk of complications and promoting safer surgical outcomes by rapidly replenishing essential clotting factors. For instance, in June 2024, according to The American Society of Plastic Surgeons (ASPS), a US-based medical organization, in 2023, liposuction (a cosmetic surgical procedure) remained the most in-demand plastic surgery procedure, with nearly 350,000 procedures performed, up 7% compared to 2022. Therefore, the rising surgical procedures are driving the growth of the balfaxar industry.

Key Players In The Global Balfaxar Market

Major companies operating in the balfaxar market are Octapharma AG

Global Balfaxar Market Trends and Insights

Major companies operating in the balfaxar market are focusing on developing advanced therapeutic solutions, such as prothrombin complex concentrate (PCC), to improve patient outcomes in bleeding disorder management. PCC is a blood-derived product containing clotting factors II, VII, IX, and X, used to rapidly reverse coagulation deficiencies in patients with vitamin K deficiency or those receiving anticoagulant therapy. For instance, in July 2023, Octapharma USA Inc., a US-based pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for Balfaxar, a non-activated, four-factor prothrombin complex concentrate (4F-PCC) used for the urgent reversal of acquired coagulation factor deficiency due to vitamin K antagonist (VKA) therapy, such as warfarin. It contains vitamin K-dependent clotting factors (factors II, VII, IX, and X) as well as antithrombotic proteins C and S. Balfaxar is provided as a lyophilized powder for reconstitution, accompanied by sterile water for injection and the Nextaro transfer device, designed for enhanced safety and ease of use during administration.

Regional Insights

North America was the largest region in the balfaxar market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Balfaxar Market?

The balfaxar market consists of sales of balfaxar syringes and balfaxar infusion sets. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Balfaxar Market Report 2026?

The balfaxar market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the balfaxar industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.